Possible Hepatoprotective Effect of Telmisartan in a Rat Model of Metabolic Syndrome

Sahar Mohamed Kamal Shams El Dine

Abstract


Metabolic syndrome (MetS), a complex of highly debilitating disorders including hypertension, diabetes mellitus, and dyslipidemia, is associated with the development of visceral obesity. Telmisartan, an angiotensin II receptor blockers and partial agonist on peroxisome proliferative activated receptor-gamma (PPAR-γ), showed a promising protective effect on MetS. The present study investigated the possible hepatic protective effect of telmisartan in an albino rat model of MetS with a focus on some proinflammatory cytokines: MCP-1 and TNF-α protein in hepatic tissue homogenates.  Adult albino rats were divided into three groups and treated for 8 weeks as follow: group 1 fed standard rat’s diet and served as normal control group; group 2 fed high carbohydrate-high Fat Diet (HCHF); group 3 fed high carbohydrate-high Fat Diet (HCHF); plus telmisartan at a dose of 5 mg/kg/day by oral gavage. A pilot study was done on the effect of temisartan alone on these markers under the regular chow diet condition and no changes were reported on their levels compared to group (1).  Administration of telmisartan in group (3) showed a significant decrease in liver index , a decrease in hepatic triglycerides, a decrease in serum ALT enzyme and a significant reduction in hepatic MCP-1 and TNF-α protein with a significant reduction in the elevated non-invasive mean blood pressure. The results indicate that telmisartan could be considered as a potential adjuvant therapy of MetS.


Keywords


metabolic syndrome; Telmisartan; liver; albino rats

Full Text:

PDF

References


Adaramoye, O. A., Nwaneri, V. O., Anyanwu, K. C., Farombi, E. O., & Emerole, G. O. (2005). Possible anti‐atherogenic effect of kolaviron (a Garcinia kola seed extract) in hypercholesterolaemic rats. Clinical and experimental pharmacology and physiology, 32(1‐2), 40-46.

Benson, S. C., Pershadsingh, H. A., Ho, C. I., Chittiboyina, A., Desai, P., Pravenec, M., & Kurtz, T. W. (2004). Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ–modulating activity. Hypertension, 43(5), 993-1002.

Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry, 72(1), 248-254.

Eslami, H., Sharifi, A. M., Rahimi, H., & Rahati, M. (2014). Protective effect of telmisartan against oxidative damage induced by high glucose in neuronal PC12 cell. Neuroscience letters, 558, 31-36.

Fan, J. G., Zhong, L., Xu, Z. J., Tia, L. Y., Ding, X. D., Li, M. S., & Wang, G. L. (2003). Effects of low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. World Journal of Gastroenterology, 9(9), 2045-2049.

Folch, J., Lees, M., & Sloane-Stanley, G. H. (1957). A simple method for the isolation and purification of total lipids from animal tissues. J. boil. Chem., 226(1), 497-509.

Fujita, K., Yoneda, M., Wada, K., Mawatari, H., Takahashi, H., Kirikoshi, H., & Nakajima, A. (2007). Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Digestive diseases and sciences, 52(12), 3455-3464.

George, J., Pera, N., Phung, N., Leclercq, I., Hou, J. Y., & Farrell, G. (2003). Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. Journal of hepatology, 39(5), 756-764.

Grundy, S. M. (2006). Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nature Reviews Drug Discovery, 5(4), 295-309.

Hennes, H. M., Smith, D. S., Schneider, K., Hegenbarth, M. A., Duma, M. A., & Jona, J. Z. (1990). Elevated liver transaminase levels in children with blunt abdominal trauma: a predictor of liver injury. Pediatrics, 86(1), 87-90.

Inaba, W., Mizukami, H., Kamata, K., Takahashi, K., Tsuboi, K., & Yagihashi, S. (2012). Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats. European journal of pharmacology, 691(1), 297-306.

Kawamoto, R., Tomita, H., Oka, Y., Ohtsuka, N., & Kamitani, A. (2005). Metabolic syndrome and carotid atherosclerosis: role of elevated blood pressure. Journal of atherosclerosis and thrombosis, 12(5), 268-275.

Kintscher, U., Bramlage, P., Paar, W. D., Thoenes, M., & Unger, T. (2007). Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovascular diabetology, 6(1), 12.

Panchal, S. K., & Brown, L. (2011). Rodent models for metabolic syndrome research. BioMed. Research International, DOI: 10.1155/2011/351982.

Poudyal, H., Campbell, F., & Brown, L. (2010). Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate–, high fat–fed rats. The Journal of nutrition, 140(5), 946-953.

Roberts, C. K., & Barnard, R. J. (2005). Effects of exercise and diet on chronic disease. Journal of Applied Physiology, 98(1), 3-30.

Shams El Dine, S. M. K. Bosentan Ameliorates Diabetic Angiopathy and Nephropathy in Streptozotocin-Induced Diabetic Model in Albino Rats. Journal of Pharmacy and Biological Sciences, 10 (1) 2278-3008

Wienen, W., Richard, S., Champeroux, P., & Audeval-Gerard, C. (2001). Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. Journal of Renin-Angiotensin-Aldosterone System, 2(1), 31-36.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2015 Advances in Pharmacognosy and Phytomedicine

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.